{"id":"W2095861620","doi":"10.1093/annonc/mdt182","title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1274,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Roche","keywords":"Medicine; Epirubicin; Pertuzumab; Trastuzumab; Breast cancer; Internal medicine; Anthracycline; Docetaxel; Neoadjuvant therapy; Chemotherapy; Oncology; Tolerability; Ejection fraction; Carboplatin; Surgery; Adverse effect; Cancer; Heart failure; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001007733,0.0009727848,0.001644261,0.00034761,0.0002725644,0.00081523,0.0006852725,0.0008977635,0.002855615],"category_scores_gemma":[0.0009596243,0.000455978,0.001009513,0.0003591161,0.0008451911,0.0008926246,0.0003392534,0.002491002,0.0004111698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004950634,"about_ca_system_score_gemma":0.0007741385,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004255143,"about_ca_topic_score_gemma":0.001221238,"domain_scores_codex":[0.9996337,0.0001909653,0.00001688153,0.00006696823,0.00002789012,0.000063628],"domain_scores_gemma":[0.9994051,0.0001456595,0.0001331355,0.00005412827,0.00002374918,0.0002382321],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9222335,0.0222537,0.003018528,0.0002878928,0.001144362,0.00007735809,0.00009874549,0.0008328478,0.008788597,0.0001240579,0.0006348289,0.04050555],"study_design_scores_gemma":[0.7182465,0.2723717,0.006448631,0.00001584252,0.0005410588,0.00009817039,0.00003799956,0.0004712522,0.0009644257,0.0001374653,0.0006508688,0.00001601145],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975767,0.0008648863,0.0002043455,0.000150281,0.00005563464,0.000377867,0.0001790967,0.00002952883,0.0005617611],"genre_scores_gemma":[0.9951816,0.001122929,0.0006279048,0.0004360022,0.0002012063,0.0007126387,0.0004733815,0.0000150026,0.001229248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002855615,"threshold_uncertainty_score":0.009553015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01326154079515388,"score_gpt":0.3152371126023836,"score_spread":0.3019755718072297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}